黃斑部病變治療市場：按類型、階段、給藥途徑、銷售管道和地區分類

2026年黃斑部病變治療市場規模估計為178億美元，預計2033年將達286億美元。預計2026年至2033年，該市場將以5.7%的複合年成長率成長。

黃斑部病變是眼科疾病，會導致中心視力喪失。它通常是由異常血管滲漏液體或血液到黃斑引起的。老齡化黃斑部病變有兩種：根治性和滲出型。目前尚無治療方法，但治療可以幫助延緩老齡化黃斑部病變（AMD）的進展並預防嚴重的視力喪失。然而，治療方法因疾病的階段和類型而異。萎縮型AMD的進展速度通常比滲出型AMD慢，但目前尚無核准的治療方法或治癒手段。萎縮型AMD較為常見，但通常進展緩慢（持續數年）。然而，治療方法因AMD的類型而異。

市場動態

視網膜疾病發病率的不斷上升、老年人口的成長、對安全有效治療方法的需求日益成長以及臨床試驗數量的增加，是推動全球黃斑部病變治療市場成長的關鍵因素。例如，根據美國疾病管制與預防中心（CDC）的數據顯示，老齡化黃斑部病變是全球主要的失明原因之一，也是65歲及以上美國人視力喪失和失明的主要原因。此外，預計到2050年，美國老年人口將從4,800萬成長至8,800萬，幾乎翻倍。

2021 年 9 月，美國食品藥物管理局(FDA) 批准了 Byooviz（ranivizumab nuna），這是Lucentis （ranivizumab 注射液）的首個生物類似藥，用於治療多種眼科疾病，核准新生血管性老齡化黃斑部病變(nAMD)，這是導致美國人 65 歲以上的主要原因。

本次調查的主要特點。

• 本報告對全球黃斑部病變治療市場進行了詳細分析，給出了預測期（2026-2033 年）的市場規模（以十億美元計）和複合年成長率（%），以 2025 年為基準年。
• 本報告指出了各個細分市場的潛在商機，並說明了該市場中一系列有吸引力的投資提案。
• 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的關鍵見解。
• 本報告根據公司概況、產品系列、主要亮點、財務表現和策略等參數，分析了全球黃斑部病變治療市場的主要參與者。
• 透過利用本報告中提出的見解，企業行銷負責人和經營團隊可以就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 透過對黃斑部病變治療市場進行各種策略性分析，相關人員將能夠更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 研究目標
• 前提
• 簡稱

第2章 市場範圍

• 報告摘要
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 全球視網膜疾病負擔日益加重
  • 缺乏對黃斑部病變的認知
  • 安全有效治療方法的需求日益成長
• 影響分析
• 主要亮點
• 法規環境
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購趨勢

第4章：黃斑部病變治療市場：依類型分類，2026-2033年

• 萎縮性老齡化黃斑部病變
• 滲出性老齡化黃斑部病變

第5章：黃斑部病變治療市場：依階段分類，2026-2033年

• 早期AMD
• AMD中期
• 後期AMD

第6章黃斑部病變治療市場：依給藥途徑分類，2026-2033年

• 靜脈注射
• 玻璃體內注射

第7章黃斑部病變治療市場：依銷售管道分類，2026-2033年

• 門診手術中心
• 醫院
• 其他銷售管道

第8章：黃斑部病變治療市場：依地區分類，2026-2033年

• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東和非洲

第9章 競爭情勢

• Bayer AG
• REGENXBIO Inc.
• Aerie Pharmaceutical Inc.
• Panoptica
• Pfizer Inc.
• Hoffmann-La Roche Ltd.
• Regeneron Pharmaceutical Inc.
• Novartis AG
• Bausch Health Companies Inc.

第10章

• 調查方法
• 關於本公司

Macular Degeneration Treatment Market is estimated to be valued at USD 17.8 Bn in 2026 and is expected to reach USD 28.6 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2033.

Macular Degeneration is an eye disease affecting the macula (the centre of the light-sensitive retina at the back of the eye), causing loss of central vision. It's generally caused by abnormal blood vessels that leak fluid or blood into the macula. There are 2 types of age-related macular degeneration, such as dry and wet. There is no cure, but macular degeneration (AMD) treatment help slow the disease and keep people from having a severe vision loss. However, the treatment depends on the stage and type. Dry AMD tends to progress more slowly than the wet type, and there is not, as of yet, an approved treatment or cure. The dry type is more common, but it usually progresses slowly (over years). However, treatment depends on the type of AMD.

Market Dynamics

Increasing prevalence of retinal disease, growing geriatric population, rise in demand for safe and effective treatment, and increasing number of clinical trials are major factors expected to propel growth of the global macular degeneration treatment market. For instance, according to the Centers for Disease Control and Prevention (CDC), age-related macular degeneration is a major cause of blindness worldwide and is the leading cause of vision loss and blindness for Americans aged 65 years and older, and the number of older Americans is projected to nearly double from 48 million to 88 million in 2050.

In September 2021, the United States Food and Drug Administration (FDA) approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye conditions, including neovascular age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for Americans aged 65 years and older.

Key features of the study

• This report provides in-depth analysis of the global macular degeneration treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global macular degeneration treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Bayer AG, REGENXBIO Inc., Panoptica, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, Aerie Pharmaceutical Inc., and Bausch Health Companies Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global macular degeneration treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global macular degeneration treatment market.

Market Segmentation

• By Type
  • Dry Age-related Macular Degeneration
  • Wet Age-related Macular Degeneration
• By Stage Of Disease
  • Early-stage AMD
  • Intermediate AMD
  • Late-stage AMD
• By Route Of Administration
  • Intravenous Route
  • Intravitreal Route
• By Sales Channel
  • Ambulatory Surgical Centres
  • Hospitals
  • Other Sales Channels
• By Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Bayer AG
  • REGENXBIO Inc.
  • Aerie Pharmaceutical Inc.
  • Panoptica
  • Pfizer Inc.
  • Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceutical Inc.
  • Novartis AG
  • Bausch Health Companies Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Stage of Disease
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Sales Channel
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing burden of retinal disorders worldwide
  • Lack of awareness regarding macular degeneration
  • Increasing demand for safe and effective treatment
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Macular Degeneration Treatment Market, By Type, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• Dry Age-related Macular Degeneration
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
• Wet Age-related Macular Degeneration
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)

5. Macular Degeneration Treatment Market, By Stage of Disease, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• Early-stage AMD
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
• Intermediate AMD
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
• Late-stage AMD
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)

6. Macular Degeneration Treatment Market, By Route of Administration, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• Intravenous Route
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
• Intravitreal Route
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)

7. Macular Degeneration Treatment Market, By Sales Channel, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• Ambulatory Surgical Centres
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
• Other Sales Channels
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)

8. Macular Degeneration Treatment Market, By Geography, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• REGENXBIO Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Aerie Pharmaceutical Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Panoptica
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron Pharmaceutical Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bausch Health Companies Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us